{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:44:39Z","timestamp":1779378279147,"version":"3.53.1"},"reference-count":122,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T00:00:00Z","timestamp":1755043200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Messenger ribonucleic acid (mRNA) technology is a promising platform for cancer immunotherapy. Unlike traditional vaccines that prevent infectious diseases, mRNA\u2019s role in oncology is to stimulate or enhance the immune response against tumor antigens. This review provides an overview of mRNA\u2019s historical development, from its discovery in 1961 to recent clinical trials and Nobel Prize-winning breakthroughs. Therapeutic mRNA flexibility allows the alteration of diverse tumor antigens. Key targets include tumor-associated antigens, which are present on both tumor cells and some healthy cells, as well as tumor-specific antigens unique to cancer cells, such as antiviral antigens and neoantigens arising from tumor mutations. Various approaches to protect mRNA from degradation, including protamine-complexed mRNA, lipoplexes, and lipid nanoparticles, as well as several administration routes, are currently being tested in clinical trials. They are focused on malignancies like melanoma, non-small cell lung cancer, prostate cancer, or pancreatic ductal adenocarcinoma, one of the most challenging cancers. While many trials are in early phases, some have advanced to phase 3 and have shown promising results in both safety and efficacy. However, due to the complexity and heterogeneity of tumors, even among patients presenting the same subgroup of neoplasm, fully universal mRNA-based cancer vaccine seems to be elusive. Personalized mRNA cancer vaccines targeting neoantigens unique to an individual\u2019s tumor have gained traction as a feasible and promising solution. Technological advances in bioinformatics, AI, and machine learning now allow for more accurate identification of immunogenic neoepitopes. The combination this type of therapy with other treatment such as immune checkpoint inhibitors may become one of new solutions in oncology.<\/jats:p>","DOI":"10.3389\/fonc.2025.1643444","type":"journal-article","created":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:18:37Z","timestamp":1755083917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":6,"title":["Unraveling the potential: mRNA therapeutics in oncology"],"prefix":"10.3389","volume":"15","author":[{"given":"Karol","family":"Gawalski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weronika","family":"Przybyszewska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaromir","family":"Hunia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alicja","family":"Gawalska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"Rymarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,8,13]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2639-4","article-title":"Phase I\/II study of COVID-19 RNA vaccine BNT162b1 in adults","volume":"586","author":"Mulligan","year":"2020","journal-title":"Nature"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2022483","article-title":"An mRNA Vaccine against SARS-CoV-2 \u2014 Preliminary Report","volume":"383","author":"Jackson","year":"2020","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-03046-x","article-title":"Pioneers of mRNA COVID vaccines win medicine Nobel","volume":"622","author":"Callaway","year":"2023","journal-title":"Nature"},{"key":"B4","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12929-023-00977-5","article-title":"mRNA-based vaccines and therapeutics: an in-depth survey of current and upcoming clinical applications","volume":"30","author":"Wang","year":"2023","journal-title":"J BioMed Sci"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1038\/190576a0","article-title":"An unst able intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/227710a0","article-title":"Adenine-rich polymer associated with rabbit reticulocyte messenger RNA","volume":"227","author":"Lim","year":"1970","journal-title":"Nature"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1038\/253374a0","article-title":"A blocked structure at the 5\u2032 terminus of mRNA from cytoplasmic polyhedrosis virus","volume":"253","author":"Furuichi","year":"1975","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1016\/S0021-9258(19)40646-7","article-title":"Purification of mRNA guanylyltransferase and mRNA (guanine-7-) methyltransferase from vaccinia virions","volume":"250","author":"Martin","year":"1975","journal-title":"J Biol Chem"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.69.6.1408","article-title":"Purification of biologically active globin messenger RNA by chromatography on oligothymidylic acid-cellulose","volume":"69","author":"Aviv","year":"1972","journal-title":"Proc Natl Acad Sci"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/0006-291X(69)90720-7","article-title":"The synthesis of mouse hemoglobin chains in a rabbit reticulocyte cell-free system programmed with mouse reticulocyte 9S RNA","volume":"37","author":"Lockard","year":"1969","journal-title":"Biochem Biophys Res Commun"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/233177a0","article-title":"Use of frog eggs and oocytes for the study of messenger RNA and its translation in living cells","volume":"233","author":"Gurdon","year":"1971","journal-title":"Nature"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(83)90054-5","article-title":"Human \u03b2-globin pre-mRNA synthesized in vitro is accurately spliced in xenopus oocyte nuclei","volume":"32","author":"Green","year":"1983","journal-title":"Cell"},{"key":"B13","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1016\/0092-8674(84)90049-7","article-title":"Normal and mutant human \u03b2-globin pre-mRNAs are faithfully and efficiently spliced in vitro","volume":"36","author":"Krainer","year":"1984","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/12.18.7035","article-title":"Efficient in vitro synthesis of biologically active RNA and RNA hybridization probes from plasmids containing a bacteriophage SP6 promoter","volume":"12","author":"Melton","year":"1984","journal-title":"Nucleic Acids Res"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1038\/274921a0","article-title":"Evidence for translation of rabbit globin mRNA after liposomemediated insertion into a human cell line","volume":"274","author":"Ostro","year":"1978","journal-title":"Nature"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1038\/274923a0","article-title":"Translation of rabbit globin mRNA introduced by liposomes into mouse lymphocytes","volume":"274","author":"Dimitriadis","year":"1978","journal-title":"Nature"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc Natl Acad Sci"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.1546298","article-title":"Reversal of diabetes insipidus in brattleboro rats: intrahypothalamic injection of vasopressin mRNA","volume":"255","author":"Jirikowski","year":"1992","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1002\/eji.1830230749","article-title":"Induction of virus-specific cytotoxic T lymphocytes in vivo by liposome-entrapped mRNA","volume":"23","author":"Martinon","year":"1993","journal-title":"Eur J Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/0264-410X(94)90074-4","article-title":"Self-replicating Semliki Forest virus RNA as recombinant vaccine","volume":"12","author":"Zhou","year":"1994","journal-title":"Vaccine"},{"key":"B22","article-title":"Characterization of a messenger RNA polynucleotide vaccine vector","volume":"55","author":"Conry","year":"1995","journal-title":"Cancer Res"},{"key":"B23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1521-4141(200001)30:1<1::AID-IMMU1>3.0.CO;2-","article-title":"In vivo application of RNA leads to induction of specific cytotoxic T lymphocytes and antibodies","volume":"30","author":"Hoerr","year":"2000","journal-title":"Eur J Immunol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1209367109","article-title":"Nonviral delivery of self-amplifying RNA vaccines","volume":"109","author":"Geall","year":"2012","journal-title":"Proc Natl Acad Sci"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J Exp Med"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M310175200","article-title":"mRNA is an endogenous ligand for toll-like receptor 3","volume":"279","author":"Karik\u00f3","year":"2004","journal-title":"J Biol Chem"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/sj.gt.3302964","article-title":"Spontaneous cellular uptake of exogenous messenger RNA in vivo is nucleic acid-specific, saturable and ion dependent","volume":"14","author":"Probst","year":"2007","journal-title":"Gene Ther"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1097\/CJI.0b013e31815ce501","article-title":"Results of the first phase I\/II clinical vaccination trial with direct injection of mRNA","volume":"31","author":"Weide","year":"2008","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics \u2014 developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"B31","article-title":"An overview of the MAGE gene family with the identification of all human members of the family","volume":"61","author":"Chomez","year":"2001","journal-title":"Cancer Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.91.14.6458","article-title":"Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection","volume":"91","author":"Kawakami","year":"1994","journal-title":"Proc Natl Acad Sci U.S.A"},{"key":"B33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.180.1.35","article-title":"A new gene coding for a differentiation antigen recognized by autologous cytolytic T lymphocytes on HLA-A2 melanomas","volume":"180","author":"Coulie","year":"1994","journal-title":"J Exp Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1084\/jem.181.6.2109","article-title":"Identification of an immunodominant peptide of HER-2\/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines","volume":"181","author":"Fisk","year":"1995","journal-title":"J Exp Med"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1617654","article-title":"Advances and challenges in neoantigen prediction for cancer immunotherapy","volume":"16","author":"Zhang","year":"2025","journal-title":"Front Immunol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-021-00387-y","article-title":"Identification of neoantigens for individualized therapeutic cancer vaccines","volume":"21","author":"Lang","year":"2022","journal-title":"Nat Rev Drug Discov"},{"key":"B37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ccell.2022.10.013","article-title":"Challenges in neoantigen-directed therapeutics","volume":"41","author":"Lybaert","year":"2023","journal-title":"Cancer Cell"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02559","article-title":"DeepHLApan: A deep learning approach for neoantigen prediction considering both HLA-peptide binding and immunogenicity","volume":"10","author":"Wu","year":"2019","journal-title":"Front Immunol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/s13073-019-0679-x","article-title":"pTuneos: prioritizing tumor neoantigens from next-generation sequencing data","volume":"11","author":"Zhou","year":"2019","journal-title":"Genome Med"},{"key":"B40","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1016\/j.cell.2020.09.015","article-title":"Key parameters of tumor epitope immunogenicity revealed through a consortium approach improve neoantigen prediction","volume":"183","author":"Wells","year":"2020","journal-title":"Cell"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines \u2014 a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2014.957684","article-title":"mRNA-based dendritic cell vaccines","volume":"14","author":"Benteyn","year":"2015","journal-title":"Expert Rev Vaccines"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00372-2","article-title":"Clinical advances and ongoing trials on mRNA vaccines for cancer treatment","volume":"23","author":"Lorentzen","year":"2022","journal-title":"Lancet Oncol"},{"key":"B44","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s12943-021-01311-z","article-title":"mRNA vaccine: a potential therapeutic strategy","volume":"20","author":"Wang","year":"2021","journal-title":"Mol Cancer"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"B46","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol Cancer"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-022-01294-2","article-title":"The clinical progress of mRNA vaccines and immunotherapies","volume":"40","author":"Barbier","year":"2022","journal-title":"Nat Biotechnol"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.5","article-title":"Nanotechnologies in delivery of mRNA therapeutics using nonviral vector-based delivery systems","volume":"24","author":"Guan","year":"2017","journal-title":"Gene Ther"},{"key":"B49","unstructured":"ClinicalTrials.gov"},{"key":"B50","unstructured":"Clin cancer trial results"},{"key":"B51","unstructured":"National Cancer Institute"},{"key":"B52","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1097\/CJI.0b013e3181a00068","article-title":"Direct injection of protamine-protected mRNA: results of a phase 1\/2 vaccination trial in metastatic melanoma patients","volume":"32","author":"Weide","year":"2009","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B53","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1186\/s40425-015-0068-y","article-title":"Self-adjuvanted mRNA vaccination in advanced prostate cancer patients: a first-in-man phase I\/IIa study","volume":"3","author":"K\u00fcbler","year":"2015","journal-title":"J Immunother Cancer"},{"key":"B54","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/CJI.0b013e3181f7dbe8","article-title":"Messenger RNA-based vaccines with dual activity induce balanced TLR-7 dependent adaptive immune responses and provide antitumor activity","volume":"34","author":"Fotin-Mleczek","year":"2011","journal-title":"J Immunother Hagerstown Md 1997"},{"key":"B55","doi-asserted-by":"publisher","DOI":"10.4161\/hv.29553","article-title":"mRNA vaccine CV9103 and CV9104 for the treatment of prostate cancer","volume":"10","author":"Rausch","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"B56","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s00262-019-02315-x","article-title":"A phase I\/IIa study of the mRNA-based cancer immunotherapy CV9201 in patients with stage IIIB\/IV non-small cell lung cancer","volume":"68","author":"Sebastian","year":"2019","journal-title":"Cancer Immunol Immunother CII"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx376.014","article-title":"Results of the randomized, placebo-controlled phase I\/IIB trial of CV9104, an mRNA based cancer immunotherapy, in patients with metastatic castration-resistant prostate cancer (mCRPC)","volume":"28","author":"Stenzl","year":"2017","journal-title":"Ann Oncol"},{"key":"B58","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s40425-019-0520-5","article-title":"Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer","volume":"7","author":"Papachristofilou","year":"2019","journal-title":"J Immunother Cancer"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-14-748","article-title":"Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive\u00ae) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer","volume":"14","author":"Sebastian","year":"2014","journal-title":"BMC Cancer"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdx712.003","article-title":"IVAC MUTANOME: A first-in-human phase I clinical trial targeting individual mutant neoantigens for the treatment of melanoma","volume":"28","author":"Miller","year":"2017","journal-title":"Ann Oncol"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2537-9","article-title":"An RNA vaccine drives immunity in checkpoint-inhibitor-treated melanoma","volume":"585","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B62","doi-asserted-by":"publisher","first-page":"TPS9107","DOI":"10.1200\/JCO.2018.36.15_suppl.TPS9107","article-title":"Phase 1\/2 study of mRNA vaccine therapy + durvalumab (durva) \u00b1 tremelimumab (treme) in patients with metastatic non-small cell lung cancer (NSCLC)","volume":"36","author":"Gandhi","year":"2018","journal-title":"J Clin Oncol"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03334-7","article-title":"Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial","volume":"31","author":"Lopez","year":"2025","journal-title":"Nat Med"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2523","article-title":"A phase I multicenter study to assess the safety, tolerability, and immunogenicity of mRNA-4157 alone in patients with resected solid tumors and in combination with pembrolizumab in patients with unresectabl e solid tumors","volume":"37","author":"Burris","year":"2019","journal-title":"J Clin Oncol"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2019.37.15_suppl.2641","article-title":"A phase I study (E011-MEL) of a TriMix-based mRNA immunotherapy (ECI-006) in resected melanoma patients: Analysis of safety and immunogenicity","volume":"37","author":"Arance Fernandez","year":"2019","journal-title":"J Clin Oncol"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e15269","article-title":"Phase I trial of personalized mRNA vaccine encoding neoantigen in patients with advanced digestive system neoplasms","volume":"38","author":"Zhan","year":"2020","journal-title":"J Clin Oncol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134915","article-title":"mRNA vaccine-induced neoantigen-specific T cell immunity in patients with gastrointestinal cancer","volume":"130","author":"Cafri","year":"2020","journal-title":"J Clin Invest"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7","article-title":"Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study","volume":"403","author":"Weber","year":"2024","journal-title":"Lancet"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y","article-title":"Personalized RNA neoantigen vaccines stimulate T cells in pancreatic cancer","volume":"618","author":"Rojas","year":"2023","journal-title":"Nature"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.678","article-title":"611O Updated results from BNT211-01 (NCT04503278), an ongoing, first-in-human, phase I study evaluating safety and efficacy of CLDN6 CAR T cells and a CLDN6-encoding mRNA vaccine in patients with relapsed\/refractory CLDN6+ solid tumors","volume":"35","author":"Haanen","year":"2024","journal-title":"Ann Oncol"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/nature12477","article-title":"Signatures of mutational processes in human cancer","volume":"500","author":"LB","year":"2013","journal-title":"Nature"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.10961","article-title":"Effects of granulocyte-macrophage colony-stimulating factor and foreign helper protein as immunologic adjuvants on the T-cell response to vaccination with tyrosinase peptides","volume":"104","author":"Scheibenbogen","year":"2003","journal-title":"Int J Cancer"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2024-CT052","article-title":"Abstract CT052: A phase IB study of mRNA-based active cancer vaccine, BI1361849, combined with durvalumab and tremelimumab immunotherapy in patients with non-small cell lung cancer (NSCLC)","volume":"84","author":"Chen","year":"2024","journal-title":"Cancer Res"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294","article-title":"Sipuleucel-T immunotherapy for castration-resistant prostate cancer","volume":"363","author":"Kantoff","year":"2010","journal-title":"N Engl J Med"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1097\/ju.0000000000003846","article-title":"Diagnosis and treatment of non-muscle invasive bladder cancer: AUA\/SUO guideline: 2024 amendment","volume":"211","author":"Holzbeierlein","year":"2024","journal-title":"J Urol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.eururo.2024.07.027","article-title":"European association of urology guidelines on non\u2013muscle-invasive bladder cancer (TaT1 and carcinoma in situ)\u2014A summary of the 2024 guidelines update","volume":"86","author":"Gontero","year":"2024","journal-title":"Eur Urol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"17","DOI":"10.3322\/caac.21763","article-title":"Cancer statistics, 2023","volume":"73","author":"Siegel","year":"2023","journal-title":"CA Cancer J Clin"},{"key":"B78","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1126\/science.aaa4971","article-title":"Neoantigens in cancer immunotherapy","volume":"348","author":"Schumacher","year":"2015","journal-title":"Science"},{"key":"B79","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1186\/s12967-023-04433-8","article-title":"The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis","volume":"21","author":"Simon","year":"2023","journal-title":"J Transl Med"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1007\/s12094-023-03108-6","article-title":"Identification of tumor antigens and immune subtypes of acute myeloid leukemia for mRNA vaccine development","volume":"25","author":"Wang","year":"2023","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1014638","article-title":"Exploitation of tumor antigens and construction of immune subtype classifier for mRNA vaccine development in bladder cancer","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.921711","article-title":"Identification of novel tumor antigens and the immune landscapes of bladder cancer patients for mRNA vaccine development","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.973712","article-title":"Identification of tumor antigens and immune subtypes in breast cancer for mRNA vaccine development","volume":"12","author":"Li","year":"2022","journal-title":"Front Oncol"},{"key":"B84","doi-asserted-by":"publisher","DOI":"10.18632\/aging.204798","article-title":"Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection","volume":"15","author":"Zhu","year":"2023","journal-title":"Aging"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020396","article-title":"LRP2 and DOCK8 are potential antigens for mRNA vaccine development in immunologically \u201cCold\u201d KIRC tumours","volume":"11","author":"Zhang","year":"2023","journal-title":"Vaccines"},{"key":"B86","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s12943-021-01465-w","article-title":"Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma","volume":"20","author":"Xu","year":"2021","journal-title":"Mol Cancer"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.4846","article-title":"Identifying tumor antigens and immuno-subtyping in colon adenocarcinoma to facilitate the development of mRNA vaccine","volume":"11","author":"Tan","year":"2022","journal-title":"Cancer Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/sji.13250","article-title":"Identification of tumour antigens and immune subtypes in the development of an anti-cancer vaccine for endometrial carcinoma","volume":"97","author":"Feng","year":"2023","journal-title":"Scand J Immunol"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.21037\/tcr-23-2027","article-title":"Identification of tumor antigens for mRNA vaccines and ferroptosis-related landscape in esophageal squamous cell carcinoma","volume":"13","author":"Zeng","year":"2024","journal-title":"Transl Cancer Res"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.853113","article-title":"Identification of tumor antigens and immune subtypes of esophageal squamous cell carcinoma for mRNA vaccine development","volume":"13","author":"Lu","year":"2022","journal-title":"Front Genet"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fgene.2022.1068112","article-title":"Bioinformatics analyses for the identification of tumor antigens and immune subtypes of gastric adenocarcinoma","volume":"13","author":"Wei","year":"2022","journal-title":"Front Genet"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.1060496","article-title":"Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development","volume":"12","author":"Jiang","year":"2022","journal-title":"Front Oncol"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.773264","article-title":"Identification of tumor antigens and immune subtypes of glioblastoma for mRNA vaccine development","volume":"13","author":"Lin","year":"2022","journal-title":"Front Immunol"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.1064754","article-title":"Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development","volume":"10","author":"Chen","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.3390\/biom13010090","article-title":"Screening of tumor antigens and construction of immune subtypes for mRNA vaccine development in head and neck squamous cell carcinoma","volume":"13","author":"Li","year":"2022","journal-title":"Biomolecules"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.4251\/wjgo.v15.i10.1717","article-title":"Identification of tumor antigens and immune subtypes of hepatocellular carcinoma for mRNA vaccine development","volume":"15","author":"Lu","year":"2023","journal-title":"World J Gastrointest Oncol"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04285-7","article-title":"Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development","volume":"149","author":"Li","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-022-04325-2","article-title":"Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development","volume":"149","author":"Fu","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/6851026","article-title":"Identifying potential tumor antigens and antigens-related subtypes in hepatocellular carcinoma for mRNA vaccine development","volume":"2022","author":"Liao","year":"2022","journal-title":"J Oncol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.7150\/jca.87184","article-title":"Identification of tumor antigens and immune subtypes of high-grade serous ovarian cancer for mRNA vaccine development","volume":"14","author":"Wu","year":"2023","journal-title":"J Cancer"},{"key":"B101","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s41016-022-00301-4","article-title":"Identification of tumor-associated antigens and immune subtypes of lower-grade glioma and glioblastoma for mRNA vaccine development","volume":"8","author":"Wang","year":"2022","journal-title":"Chin Neurosurg J"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11757-7","article-title":"Screening of novel tumor-associated antigens for lung adenocarcinoma mRNA vaccine development based on pyroptosis phenotype genes","volume":"24","author":"Zhou","year":"2024","journal-title":"BMC Cancer"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3219","DOI":"10.1038\/s41598-024-53622-y","article-title":"Discovery of lung adenocarcinoma tumor antigens and ferroptosis subtypes for developing mRNA vaccines","volume":"14","author":"Chen","year":"2024","journal-title":"Sci Rep"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.csbj.2022.08.066","article-title":"Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma","volume":"20","author":"Zhao","year":"2022","journal-title":"Comput Struct Biotechnol J"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2022.108816","article-title":"Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma","volume":"109","author":"Zhou","year":"2022","journal-title":"Int Immunopharmacol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.755401","article-title":"Potential immune biomarker candidates and immune subtypes of lung adenocarcinoma for developing mRNA vaccines","volume":"12","author":"Wang","year":"2021","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.21037\/jtd-22-1113","article-title":"Identification of tumor antigens and immune subtypes in lung squamous cell carcinoma for mRNA vaccine development","volume":"14","author":"Zhao","year":"2022","journal-title":"J Thorac Dis"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-022-01290-y","article-title":"Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine","volume":"40","author":"Ping","year":"2022","journal-title":"Invest New Drugs"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081168","article-title":"Identification of tumor antigens and immune subtypes of Malignant mesothelioma for mRNA vaccine development","volume":"10","author":"Wang","year":"2022","journal-title":"Vaccines"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.879278","article-title":"Identification of potential antigens for developing mRNA vaccine for immunologically cold mesothelioma","volume":"10","author":"Zhang","year":"2022","journal-title":"Front Cell Dev Biol"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000038666","article-title":"Identification of immune- and oxidative stress-related signature genes as potential targets for mRNA vaccines for pancreatic cancer patients","volume":"103","author":"Li","year":"2024","journal-title":"Med (Baltimore)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12040726","article-title":"Identification of novel tumor pyroptosis-related antigens and pyroptosis subtypes for developing mRNA vaccines in pancreatic adenocarcinoma","volume":"12","author":"Lin","year":"2024","journal-title":"Biomedicines"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3390\/jpm13020359","article-title":"Identification of five tumor antigens for development and two immune subtypes for personalized medicine of mRNA vaccines in papillary renal cell carcinoma","volume":"13","author":"Hu","year":"2023","journal-title":"J Pers Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/14760584.2024.2396086","article-title":"Screening of tumor antigens and immunogenic cell death landscapes of prostate adenocarcinoma for exploration of mRNA vaccine","volume":"23","author":"Yu","year":"2024","journal-title":"Expert Rev Vaccines"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1037808","article-title":"Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development","volume":"13","author":"Chen","year":"2022","journal-title":"Front Immunol"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyad193","article-title":"Identification of immune subtypes and candidate mRNA vaccine antigens in small cell lung cancer","volume":"28","author":"Wei","year":"2023","journal-title":"Oncologist"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14020448","article-title":"Identification of tumor antigens and immune subtypes for the development of mRNA vaccines and individualized immunotherapy in soft tissue sarcoma","volume":"14","author":"Wu","year":"2022","journal-title":"Cancers"},{"key":"B118","unstructured":"The cancer genome atlas program (TCGA)"},{"key":"B119","unstructured":"Centivax\u2019s $45M moonshot: the race to end flu pandemics forever\n          \n          2025"},{"key":"B120","unstructured":"Clinical trial of mRNA universal influenza vaccine candidate begins\n          \n          2023"},{"key":"B121","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1126\/science.abm0271","article-title":"A multivalent nucleoside-modified mRNA vaccine against all known influenza virus subtypes","volume":"378","author":"Arevalo","year":"2022","journal-title":"Science"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06800-3","article-title":"N1-methylpseudouridylation of mRNA causes +1 ribosomal frameshifting","volume":"625","author":"Mulroney","year":"2024","journal-title":"Nature"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1643444\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,13]],"date-time":"2025-08-13T11:18:45Z","timestamp":1755083925000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1643444\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,13]]},"references-count":122,"alternative-id":["10.3389\/fonc.2025.1643444"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1643444","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,13]]},"article-number":"1643444"}}